Added to YB: 2026-10-09
Pitch date: 2026-10-04
OSTX [neutral]
OS Therapies Incorporated
-12.42%
current return
Author Info
No bio for this author
Company Info
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Market Cap
$68.7M
Pitch Price
$1.61
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.88
P/E
-1.42
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - OS Therapies Incorporated
OSTX (hold): OS Therapies is a narrow osteosarcoma immunotherapy thesis at $1.62. The disease’s scarcity creates need, but not necessarily commercial scale, while the potential buyer universe is limited to pediatric-oncology, sarcoma or rare-oncology organizations. Strategic appeal depends on clinical evidence becoming strong enough to justify specialized development and commercialization.
Read full article (1 min)